About Syros Pharmaceuticals, Inc.
https://www.syros.comSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.
CEO
James E. Bradner
Compensation Summary
(Year 2021)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-09-19 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
Shares:4.81M
Value:$961.33
CHI ADVISORS LLC
Shares:1.3M
Value:$259.87
BLACKROCK INC.
Shares:259.19K
Value:$51.84
Summary
Showing Top 3 of 16
About Syros Pharmaceuticals, Inc.
https://www.syros.comSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2024 | $0 | $26.18M ▼ | $-6.4M ▲ | 0% | $-0.16 ▲ | $-4.76M ▲ |
| Q2-2024 | $0 | $27.42M ▼ | $-23.33M ▼ | 0% | $-0.59 ▼ | $-21.61M ▼ |
| Q1-2024 | $0 ▼ | $30.59M ▲ | $-3.71M ▲ | 0% ▲ | $-0.1 ▲ | $-2.07M ▲ |
| Q4-2023 | $386K ▼ | $27.11M ▼ | $-64.38M ▼ | -16.68K% ▼ | $-2.18 ▼ | $-62.78M ▼ |
| Q3-2023 | $3.76M | $38.4M | $-40.14M | -1.07K% | $-1.43 | $-38.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2024 | $58.27M ▼ | $85M ▼ | $96.12M ▼ | $-11.12M ▼ |
| Q2-2024 | $78.96M ▼ | $106.72M ▼ | $113.07M ▼ | $-6.35M ▼ |
| Q1-2024 | $108.3M ▼ | $134.73M ▼ | $119.67M ▼ | $15.06M ▼ |
| Q4-2023 | $139.53M ▲ | $168.17M ▲ | $151.51M ▲ | $16.66M ▼ |
| Q3-2023 | $112.22M | $147.79M | $111.49M | $36.3M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2024 | $-6.4M ▲ | $-20.69M ▲ | $0 ▼ | $0 ▼ | $-20.69M ▼ | $-20.69M ▲ |
| Q2-2024 | $-23.33M ▼ | $-29.67M ▲ | $25.07M ▲ | $41K ▲ | $-4.56M ▲ | $-29.67M ▲ |
| Q1-2024 | $-3.71M ▲ | $-31.1M ▼ | $-24.64M ▼ | $-265K ▼ | $-56M ▼ | $-31.1M ▼ |
| Q4-2023 | $-64.38M ▼ | $-18.57M ▲ | $1.52M ▼ | $43.38M ▲ | $27.31M ▲ | $-18.6M ▲ |
| Q3-2023 | $-40.14M | $-31.86M | $28.64M | $-5K | $-3.22M | $-31.86M |
CEO
James E. Bradner
Compensation Summary
(Year 2021)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-09-19 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC
Shares:4.81M
Value:$961.33
CHI ADVISORS LLC
Shares:1.3M
Value:$259.87
BLACKROCK INC.
Shares:259.19K
Value:$51.84
Summary
Showing Top 3 of 16